Endothelin-converting enzyme inhibitors and their potential for cardiovascular and renal therapeutics

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.14, Iss.5, 2004-05, pp. : 655-665

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1537-1552

Informa Healthcare

Access to resources Recommend Favorite

Phosphono substituted tetrazole derivatives as endothelin-converting enzyme inhibitors

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 3, 1997-03 ,pp. : 277-280

Informa Healthcare

Access to resources Recommend Favorite

Isoforms of endothelin-converting enzyme: why and where?

By Turner A.J. Barnes K. Schweizer A. Valdenaire O.

Trends in Pharmacological Sciences, Vol. 19, Iss. 12, 1998-12 ,pp. : 483-486

Elsevier

Access to resources Recommend Favorite

The membranes of cultured rat brain astrocytes contain endothelin-converting enzyme activity

By Deschepper C.F. Houweling A.D. Picard S.

European Journal of Pharmacology, Vol. 275, Iss. 1, 1995-02 ,pp. : 61-66

Elsevier

Access to resources Recommend Favorite

Expression of human endothelin-converting enzyme isoforms: role of angiotensin II

By Schubert A. Morawietz H. Goettsch W.

Canadian Journal of Physiology and Pharmacology, Vol. 86, Iss. 6, 2008-06 ,pp. : 299-309

NRC Research Press

Access to resources Recommend Favorite